<SEC-DOCUMENT>0001193125-12-334883.txt : 20120803
<SEC-HEADER>0001193125-12-334883.hdr.sgml : 20120803
<ACCEPTANCE-DATETIME>20120803162034
ACCESSION NUMBER:		0001193125-12-334883
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120801
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120803
DATE AS OF CHANGE:		20120803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRISTOL MYERS SQUIBB CO
		CENTRAL INDEX KEY:			0000014272
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				220790350
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01136
		FILM NUMBER:		121007074

	BUSINESS ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154
		BUSINESS PHONE:		2125464000

	MAIL ADDRESS:	
		STREET 1:		345 PARK AVE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10154

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BRISTOL MYERS CO
		DATE OF NAME CHANGE:	19891012
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d391940d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 OR 15(d) of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>The Securities Exchange Act Of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;1, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>BRISTOL-MYERS SQUIBB COMPANY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-1136</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22-079-0350</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification&nbsp;Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>345 Park Avenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>New York, NY, 10154 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Office)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: (212)&nbsp;546-4000 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<I>see </I>General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;1, 2012 Bristol-Myers Squibb Company (the &#147;Company&#148;) issued a press release announcing that it had suspended study drug administration in an ongoing Phase II study of BMS-986094
(formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the
safety issue and any potential relationship to study drug are unknown at this time. The Company acquired BMS-986094 when it completed its acquisition of Inhibitex, Inc. in February 2012.&nbsp;The carrying value of this in-process research and
development intangible asset was $1.8 billion as of June&nbsp;30, 2012.&nbsp;The Company is assessing whether an impairment is required. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exhibits. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release of Bristol-Myers Squibb Company dated August&nbsp;1, 2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRISTOL-MYERS SQUIBB COMPANY</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: August&nbsp;3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Sandra Leung</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sandra Leung</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Counsel and Corporate Secretary</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press release of Bristol-Myers Squibb Company dated August 1, 2012.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d391940dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g391940ex99_1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B
Nucleotide for the Treatment of Hepatitis C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Princeton, NJ, August&nbsp;1, 2012) - <U>Bristol-Myers Squibb Company</U>
(NYSE: BMY) announced today that the Company has suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C.
This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With patient safety as the priority, the Company is undertaking an immediate assessment of all patients in the study and following an
evaluation of the patient data, will take appropriate actions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Bristol-Myers Squibb </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases. For more information, please visit <U>www.bms.com</U> or follow us on Twitter at <U>http://twitter.com/bmsnews</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"># # # </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Media:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sonia Choi, 609-252-5132, <U>sonia.choi@bms.com</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investors:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Elicker, 609-252-4611, <U>john.elicker@bms.com</U> or Timothy Power, 609-252-7509, <U>timothy.power@bms.com</U></FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g391940ex99_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g391940ex99_1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`(@#Z`P$1``(1`0,1`?_$`+L```("`P$!`0``````
M```````(!PD%!@H"!`,!``(#`0$!`0`````````````'!`4&"`,"`1````<`
M`0,#`0()"04)`````0(#!`4&!P@`$1(A$PD4(A4Q05$R,S46-E9A0B,T9!<W
M.`KP<8%B.;'Q@H-4)65F&!$``@$#`P,"`P0%"`D%`0```0(#$00%`!(&(1,'
M,2)!,A1183,50E)B(PAQ@5,T5!8V%Y&Q@K)C<X,U-_#1\7)5=?_:``P#`0`"
M$0,1`#\`[J]5OQ<WI4C8D&`S<\X<,*_3:VFH5)>TW>Q.THBJUY$XB`I)R$NZ
M3^H6]0:M"JKG^PD80M,/C3E+];9F[=N`7E?X1Q(-TC_S*#0?I-11U(U4YO*#
M$8Y[I5[ER2J11UH9)I#MC0?9N8C<?T5W,>BG5(43DMD#8ZU-[C?#W:=TF<T>
MFPU\N"#V=H+FR5?7;17D*M8J<G(QB"=<8SJQ8UDJQ7CY5M&S$7X.3$8N@,^Y
MLS:_DDL&`M^Q;VL<,K11D),$DMXW,B2;6.\H-[!P\;/'-5`9$USC!@[O\_AN
M>1W/U%S=RW$232@O"9([J2,1R1;E`C#D1H49)%CEAHY$;U;!UEU2E'UOHI.-
M>49C8\TB&4WJFKVB=>VS,:]7I%G(/H^P42#82D/:;B[?1T0[<&:2R<$C&^T`
M+JN?LE5QZ9:\B2"_.4O+NVNG*V]O&@CG=U(!25RK1Q@%E&Z,REZ^T+U(W#X:
MQFDGQHQ%C9W5G&'N;F1S+;QQL&97A16224E49ML@A$=/<S]`RP8%#Z#E6A1N
MRYK*7<N;2TKK-BGLYEW2KYYJE1H3&FQMF<!#(@E%1$S2X2246AXZ+2;-R6%M
M(M!*=,Z1AU?(YL;F,8V#RB6YRB);HDR@`6\DQE:,;C5F65E`D>0L>RT3U!!&
ML9QB#*X3*IG\.]S^4.]S(\#$DW,4`B60[!15>)&)BCC"KWUE2A!!U?%%2L;.
MQ<9.0SYM)P\S'LY:)DF:I5FDA&R+9-VQ?-5B")%6SMJL50A@]#%,`]<]30RV
M\SV\ZE)XV*LIZ$,IH01]H(H==-03PW,*7-NP>"1`RL.H96%00?B"""-??_M_
M(`?E'\@!UY:]=(3<_D]X+4BVR5#=[]"6BXPQG83-?S*N776'L0#`_M/SR1LV
MK=H;,R,5?LK"=0/:-Z&[#Z=,2Q\4<_O[-<@F.DALGIM>=XK<-7TV]]XR:_"@
MZ_#2SR'F+QQC;UL;)DXYKY*[DMXYKDKM^:I@CD`V_I=>GQTQ.$<D,+Y-U)>\
M8+IM8TVM,WOW9)NZ^Z5^KA9/VP5^[IZ'?(LYF#?"F/D5)VW1.8OJ`"'KUF>0
M\7Y!Q2\%AR&TEM;IEW*''1E]*HP)5Q]ZDC6KXWROCO+[(Y#C=W%=VJM1BA-4
M)%0'1@'0D=0&45'4=-3;U0ZT.L3#3\#8VR[VO3<1/,VSYY%N7<+),I5JWDX]
M46\A'+N&*RZ23]BN42+(F$%$CAV,`#U[3VUQ:N([F-XY"H8!E*DJ>H8`@=".
MH/H1Z:\+>ZMKM#):R1RQABI*,&`9>C*2":$'H1Z@^NLMUXZ]]'1HT=&C4+9_
MR,PK5[Y?<QS/4Z=?+SER4:KH,%5)5.;-5/O9R_9L6\I(,06BB/S.XQ=-1L1<
MZZ!TQ!4A!$.][DN,<@P^/M\KE;2>WQ]V6[+R+M[FT`DJ#1J48$-2A!Z$ZS^+
MY7QS-Y*YQ&(O(+G(V87O)&V_M[B0`S"J[JJ05#%E(]P&MRT?2*-D5*GM&TFR
M,:C1ZNV2>6"QR97)F$4U7=(,DW#KZ1!RN5$7+DA1,!!`OEW'L`"(0<7B\AFK
M^/&8N)IK^8D(BTJQ`)H*D"M`=3\ME\;@L?+ELO,L&.A`+R-6B@D`$T!-*D?#
M6OXUN>0<AJ=_>#B.AUG3:7]ZOH,UBJK\'[!*8C`1,_C%Q$J:K=XV(Y3.8ARE
M,*:A#!W*8HC)SG'\UQJ]_+L];2VM]L#;)!0[6K1A]H-"*CX@CU&HV!Y'@^46
M/YGQ^ZBN[#>4WQFH#"A*GT((!!H1Z$'T(UA]QY)X-QIA82P[UJM0RN&LDHK"
MP#VV2/T19>40:G?.&;!)--9PY4;M$Q.H)2"4@"'D("8O?VP'%^0\IGDMN/6D
MUW/$FYQ&*[5)H"?0"IZ#[?YM>'(N6<;XE;QW7)+R&SMY7VH9#3<P%2``">@]
M32@Z5]1J1Z3=:MHU2KU[I$RVL-1M<6VFJ].,R.$VLK%O"^;9ZW(Z1;N`26+Z
ME\R%'M^+JLO["[QEY)C[]#%>PN5=#2JL/4&A(Z?RZM<?D+++6,62QT@EL9D#
M(XK1E/H14`]?O&MHZB:F:.C1HZ-&CHT:.C1JOJT?*I\?-.M4W3I[D[1TY6M/
MUHJPO(QA:[!68630441482-Q@*_)51NZ*LD8GB+SU4#Q_.].F1:>(O(][9QW
MUOBIS#*H9`QC1V4]:B-W60BAK\OIU]-*^\\S^,;&^?'W&7@^HC;:Q597C5@2
M*&5(VCK4$?/Z]/73E9AIE'V;/:AJF:SR%GH5\A&EBJL^V0=M492(>E$6[DK5
M^@U>MC")1*9-9,BA#`(&*`AVZP^6Q5_@\E-B,I&8LA;R%)$)!VL/45!(/\H)
M!^&M]B,MC\]C(,QBI!+CKB,/&X!&Y3\:,`P/P((!!Z$:WOJOU9:.C1K$R\_`
MU]-DM/S<1!I24DTAHY68DV48G(3$@82,(IB=ZN@5W)/3E$$4$Q,JH(=BE'KV
M@MKBY++;1O(54LVU2U%'JQH#11\2>@^.O">ZMK4*UU)'&KN$7>P7<S?*HJ15
MC\`.I^&HL)R,PI;9T>.S;4Z<^V]6$DK$IF<;*IR5HCX>)2:KOG<TS8`X)!"F
MW>I*$2>G0663.!DR&+W$+<\8Y`N#/)7M)UP/<""=EVQLS5`"DTW]002H(!Z$
MC5,.5<<;/CBR7D#<AV%S`K;I%514EPM0AH:@.5)'4`C6^7J_4?,*K+WG1[=7
M*+38!N#J:M%LF&,%!QJ)CE23%U)2*[=LF==8Y4TB>7FJH8I"`8P@`U^/QU_E
MKQ,?BX9;B^D-%CC4N['[E4$]!U)]`.IZ:LLEE,=AK*3)9:>*VQ\0J\DC!$4>
MG5F('4]`/4F@'77Q9EIE#V2A5G3\QLC*X4&Y,!E*Q9HXCI-C,1Y7"[07;8CU
MNU=`E]0V.4/-,HCX]^W;MU]Y7%9#!Y&7$Y6)H<C`VUT-"5-`:&A(]"/0Z^,1
ME\=G<=%E\3*LV.G7<C@$!@"14!@#Z@CJ!K>NJ_5CJO2Q[Q%WWD!,Q]"CV>E2
M&#NGM2KT+]_LH&C0FJR[`&USO.BW-V"S&%;TR!?A"1S-JA(S2SAU*BFS$@)K
M%9=KQZ7'<<23(LUK'D`)';87E>W4UBBAB%"QE<=UV8I$`L-7K5=*F[Y-#E.4
M218Q%O)<83%&F\)"ERXI+-/*:A!$A[*(JR2EFFI'2C:C+5:K8XG&;#GVH!1[
MK$'G[?I=9U/*W#H1HURM4]/VF5@;M1G,G*6A.D.3V5[$??T2J_62CU@<.635
M1(%^K7#WEM/G(LCBN_!-VXX'@N`/WL4:)&KQ2A5C[HV))VI`@+C:LC@[=4V;
MLKR'C\N*S/TUQ`99;B.YMB?W,LKO(R30EFD[)[CQ=Z(N0AW/&A7=I-5N6*6I
M)2%->6C[M=:@GA=;M=[(@>5;75E5XNX.8]>JM8I)VM;)J>1;C)2D9'E6,F\B
MW$6J4I'13];A>'MB66]CAW+:&[>.*NTQ&1HP1(6H(T2NR.1Z56191U0C6`;F
MXS2MCY)]CWHLXY)J;A,L:RE3$%!,KN!W)(TK1HWA:@<'5C,2TT@CW-+M0*YF
M%'J6,5J>J](Q^_79JEH=X@+*V@T9.2LEG@7,K7,]LID:^BJU:JIS1W#E949!
M=JH<0264SXPQW5AD9;NXO+Z5));F&(]F)T+E52-PKS)5R&8&+:H';5P.K8@C
MRPDL\CBX;.VL<?"\<-K-,._,D@0,TDB%HX)*("JD3%F+=UD).W9>,&QT\+Q<
MN/#=1U7)"&:.M%H5`LOT32TUFG2LL*5GIH(LG3Z+FH:D6EZ!HQ_&.GT:I#2;
M1%)81:J`$3EF$O3CX.2L!+$Y$,TR5,<DBK^[EJ0&5I8Q[TD5'$J.Q7WC4WAG
M(+`9*XXHI,4L:F>&"2@DCB9J214!*ND,A_=O&SQF*2-5;V'3R=@'T$`$!]!`
M0[@(#Z"`@/H("'2_]-,GUZ'7,%P,U?".*/.KY@+WI,C!9AG=>VFNU6,>1M7D
M'+.+^]+?I#IM!1,-48:1>-FSU5AY^TBW*CY)@)NW8.NK_(>'Y#S#Q_PO'XM9
M+O)R6+R,&D`+;8H`79I&`)&[U)KUUQ]XWS7&N$^1N<9/+-'9XJ*]2-2L;$+N
MGN2$5(D8@';Z!:=!7T&I%^->=I*/(GY&?DE:3E?S+AMH3EJE7V:T@Q4E'1X>
M30>RNC66BUM64EJ@5XY2=+-F[YNC(+FE5?%'L4PC6^4;>_;C7&?%[QR77-[8
M'>:':-RD+"DKA5DH-H9E8H!&M6ZC5IXEN\:.3\I\L))%:<#N6]@)7<=K@M,\
M,99HZD.RAU#DS,`O0ZL.S/Y:.#NQ6BH4RCZ+995]>82ZS3%ZIF]Z;P,9&T=M
M./IW]I9W[E%A7G(P<"M()HN#D6!DH@HH5/WT0.M,KX<Y]A+2:^O[:)([=XE(
M[T1=C*4";%W5<;G"$CIN#`5VL0T<3YN\=9Z[AL,?=2O)<)*P)@E"*(@[/W&V
MT0[(R]#U"E"VW>H,.\2MY^-'BEQ0V#7./MRLD?Q[:<@[-'6&=F6=XL$O:]?G
MT8$H05#AY=D-CG47[=RT0CDD&P"H5,YSB;Q45ZNN8\>\I<OY?98;D<,3<C;&
MHR(IB18[=2_OE93L0@ABY+="0`.H75)PGDWB?AW#+[.<9GF7C2Y)U=V65VDN
M"D=%A5AO<%-@2B]0"S'HS:W/:_DFR]SB7)R,J$;R"S;:,\P.9NK*OVS"-"KE
MXK9[9'6"$I%R1B'<&[.,%'V%HDJ[E`*I&QI#%.Y5)V,4(6!\799,]BI;U\;=
M8.YR*Q%X[N%XG[;(TL98,/>4)"Q]'<U"@]#J9R+RUAWX[F(K!,G:9^UQKRA)
M+.9)H^XKK%*$*'V*^TM)0QI4;F!!`C;X_>?&5U7XW<NU?DCI5WB75$K,=&7[
M1-1K=\%Q>[A99^SKQC&C3\M$JK:Y,/09F3\80\@9(2>)_`I?2T\C>.\Q>>3K
MK$<8M8'6XE+10P/#2*-$C#&5%:ENHK7][LK7I6NJWQIY+PEGXLM<SRBZN4-M
M'26:XCGK+(\DI587=2;EJ*12(N5I[J`:;_+?D+X[Z;I-:R!U_>AD>DWJ/5EL
MZJV\Y5<\A>:1'(I>\JO175MCFD=/N"(]C_2D6*\["']%W].L7EO&O)<5BY<T
MGTE[B[=MLTEI<1W`@)Z4E$;%D%?TB-OWZW&&\I<6R^6AP;_66.5N5W01WEO+
M;&=1U)B,BA7-/T:[ONTB_`^*BX7Y:OECCX:-CXA@FWX]KD8Q;-LP9D7>UAR\
M>+D:M$TD"K/'BYUE3`7R45.8YA$QA$6!Y"FFG\.</DG=GDK>"K$DT$@`%3UH
M``!]@``Z:6WC6&&W\V\UB@14B`L^B@**F.I-!0=223]I))ZG5SU_*4]#NY#E
M*<AZA9BG(<H'(<IH5Z!BG(8!*8I@_"`^@ATC<;49&W(]>\G^\-=`90`XRY!Z
MCL2?[AUR=?#W>[#P@U+CC3;G+.E^/GR496RM-'E'H`G'U7D15)N5K*]>*IX`
MDF:;;MT&GI]I;Z^.\A'VC==A>:L?;\^Q.3OK%`.1\7NS'*H^:2SD19-_^R26
M^[9+3U&N*/!.0N?'67Q=A?R,W&>5V@>)CT6.\C=H]G^U0(?B>Y#7Y3K5_F,M
M4SR(T.D[TA)K&QG*>6M?XD8U'%.48JUSM=;.K'ONC^(^:+IL:\1S*N,UB&]M
M1.%7'U[^DOPG9P<:QL_'64?GEYAWR-RWZ4:.0EI#]H/:+3,/4&5=0O.]Y<<J
MRD')5<_D%EF5QMJOZ,CQJTEY/]X,H2%".A$1.NF6I\V^/ESY#3G%2`FK@;<:
ML@_=3]->YAH40E#Q$8DF<T^[FY*MM(!&M/2K(@S?@X%H[%=($3G%0@#RO><#
MY)9<:CY?<)!^0RE0D@GA8LS?H!%<OO%#N3;N6AW`4.NN;'R'Q>_Y1)PNV>X_
MO#"&+Q&WG4*J`$N7:,)L-5VONVMN7:3N%=>E?D*XJUU[N#.VWJ=I1..96P:_
M)73/+]5X:KO)-R@VK\0E+S%<:L)V=M8.2+1#%@=RZDVQ@6;IJ)?;ZDQ>-N77
M,=@]G;QSG)U^F6*:&1I`H)=MJN2B1T(D=PJHWM8@]-19?*7"[:7(Q7EQ+!^5
M4^I,L$\:QEB`BAFC`=Y*@Q(A9I%]R`KUUA,R^1_C+I5[0S1P^T;*[O*TY_H5
M4@-ORVYY2ZO='BV3B3D+-2!M$8V2L+)K&M%7!DDC`[]E,Y@2[$-VD97QARK%
MX\Y55M;NP2<0R/:SQ7`BE8A0DO;8["6(%3[:D"O4:\,1Y7XCEL@,4[7=E?O`
MTT:7=O+;F:)5+%XNXH#C:K-0>X@$@=#2,H#YA^!%KL\!5*MJ=AL<C9-)+ET:
MXA\UOKR.3FUACTVDO)O"0(!#59^Z?BBW?.BHE6,V<&*44D%5"VESX4\AV=I)
M>7=I'%%%:]\AIX@=HK55&_W2`"I5:TW*":L`:BU\[^-+V\CLK.\EEEDNOIP5
M@F*[CM`9CL]L;%J*Q`KM<@;49AM%;^4GBK;9>K-X%76WM.O>J1^,T78C8Y>6
MV+7&_24[^S:,9!:2ZC$8%5L67`4OJ%3(HJ"`^T*@@(=1;KQ+RZSAF:X^C6^M
M[1KF6V^IB-U%"J;RSP!BX.WK05(^--2[3S+PN]GA6V-\UA<WBVL-U]+*+669
MG$85)RH0C<:5-`>M*T.GATNL2-USG0:9$2IH*6MU(ME7BYP@JE/#2,_`OXIE
M*D,CV6*:/<NRK`)/M!X>GKU@<5=Q6&4MKZ=.Y##<1R,GZRHX8K]GN`I_/IBY
MBSER.)NL?`_:GGMI(U?]1G1E#=.OM)KT^S7,Q\8_)O.N%$=8/BVY]9;$8W;%
M+;90B+K<(A@[R_7&%T?'!%O:9AZV-'.F,EY^Q%RZHJQ;IE[:"IVRR/@IU1Y4
MXKD^=21>6?'5V]]9B%-T4;$3VYB'4QJ#N!7UDC%)%:K`,&J.1O$G+\3P%)O$
M'DNR2PO#/)MEE4&WN%E/02,1M*D>V.4UC9`%)0KUN[E;MQ1^,7CI2:M-6A]3
M,KB9J1K675A0\S?+C/R]LGI6SMJ71H6-;/[#8Q;.)=1-F@DFH#9H5(AS@``8
M4-#8<P\K<FGNX(EGRSH'G?VQ1HL:+&9968A$J%!8DC<U2!KH:;(\,\1<6M[.
MXF>'$+(R6Z$M-*[2NTG;B4`N]"QVCT5:5/QUH%3^4OC1;-8K^)J16S4?1I2"
MN=QGJ[JF2VC-']'HE)ITA<WUVLC:UMV"ZT!)LHXZ#(T>5ZLJX`P&(0I#&"QO
M/$G*;/#R9T/8W&,22*-'M[B.<2RRR+$(D,9(#J6!;?M`'H233559>9>)7N:B
MP!CR%ODWCEE=+BVD@,,,432F602`'8P4A-F\DUJ`!74F4SY">)EZP.^\GX73
M11PO.+?,TBPWR4K5ECVIYJ%"*]XT5%*Q1IV29/#3+<K90C8!6,?T*``(]5=[
MXVYC8<BM^)SVM<_=0K*D2NA.UMWS-NV*1L;<"W2FKBP\H\)R'&KGF$%W3CMI
M.T3S-'(!N4*?:NW>P;>NTA>M?32D<OML^-GD=B_$30>1EEMCFG:%I]-TCCA%
MQ#2[0=KLEI3ERUUB+^)A6XJ-H8%9(`>E>G0$B/VDSE.'6QX9@?)_&<YF<=QF
M*$7MM:R0WK,8FC1-N\T9CU;V^W:#UZ$4UB^;\B\5<HP>%R7*)9S9W5TDUDJB
M19)'![9JJCHGN]VX@TZJ:TU!.TV:LY)\Z%,OKFLS+Q!'@O8I.7C<[I,E:KC:
M)=W<):(:?2UVJQSN:L4RX$4$`4,0PIHD`5%"(IB)=#@[2[S/@&?')*BDY]55
MII5CCC41HQJ\C!44=32O4GH"QZY?/WEE@OXBH<F\,C`<>+,L$+22R,9)5%$C
M4L[GVBOP`ZD*.C<ZERMX]\O^'G."O4PT@XM&4X[J<9I.4ZG1W]3OU#GV](L#
MN&<3U+M;(CEL8KQB*C1XD"A"+H]R*%4*';&X?B').%\VP%S?;1:7E[;M#<6\
MHDAE0RH&"2QFAZ&C*:$@]00=;C.<TXQSG@7(K6QW&\L\?<B>VN(C'-"XAD*%
MXI!4>Y2585HR^H8:5[@1STP;C+P$X;U[9T=2JE>4SZM0DGK9LFO+W%Z[-6B;
MFEH:,GM*:Q*D"V<N$CE%0R1ED6XCXJG(<#%#5^0_'G(>5>0\W<X,VDUR+AV6
MW^HB%RZQHH9D@+;R`?2M"?4`BFLGXY\D\;XCXZPMIG5O8;7L*K7/TTQM4:21
MRJM.%V5IU.W<%_2((-+S/VIK'\20'Z@_:O\`7$?^ZW\2_P!8_4']L_J__-T@
MOH[O^BD_$[?RM^)^IZ?/^S\WW:Z'^NLOZ:+\+N_,OX?])Z_)^U\OWZJ,L7%E
M:#V[564U!S&NP4E).-1@ZK"N*C4-`;T.QO2EEW%%<J0K2MWQ[3[(*[1]&2:K
M&1,@X8KD?KJ.2MQ<UKRU9\#9R02)97"H('D8220F5![1*-Q>$2)1DDC#)42*
M8U"EM(F[X6;;D=['<127]L[FX2)#%%.(9#[C"=@CF,4E5>.0I)1HV$K%PFM?
MM.48=+4J?N>0U&_-ZG64'J5AU#3&PUB'B;"S?C"JTNHT>2KD3;+]H2=E(:),
MU,$;$-Y+^C4?*'(9`95IF.00WT=CFI[<WDI&R"`]QF0C<)9)5=HX83'^\W#?
M(4ZB,`AM1;W"<;GQ\N0P4%R+&$$/<7`[:JX;9VHH6C66><2?N]O[N)9.AD)!
M72IMZ]K?[/YQ"Z!;V;7)JA(5J2@9IQ1J<=V+;3XRU2TW*71*'K\2Y3KMK3B3
MR\::*&/>-XF+\1,NY>%2/KVN<-]3=7&-@8YB975U$LM*P-&JK%N=AOCW"-^Y
MO4R25]JH6&)6USOTEI;Y6=5P<#1LCF&*M+A9&=I@B*>W*$[L9BV.L4=*L\@4
MNJIB&(0#IG3+KCFRH:[,INCTZH49]"7"IZ2W9^Q]9.TG1UJ[#UMC78U-XW4?
MGL!X5W'IKD$Z)P.D97"C/Y^X1KZPOK$X6,CN22AHY(":T26`.SEVH0@A$JN0
M:,*$!AGCO'+5UQ^0Q]^,[(#VHH2DL5P!2KPW!C2-8UJI<SF)D#"JFJEI(XF\
M>Y"N[_<]!._9Q->SZO.:"6EP(Q,_",K_`&$S"6G8\U^=UN*L5GD*972M6[]5
MJG&1@R,@H@5N=1D=0:KF7)(KGCD&."L]S<R";NON1C"E55NR'9(UE?<4#%WV
M(&W`.!JWX-Q66UY1<93<J6EK$8>TFUT$[[6=>\8U>1HDVJY41Q]QRH0F,G5G
M_D4@"<Q@*4H"8QC"`%*4OJ8QA'L`%*`=Q'\72F`)-!ZZ<Q(`J?37.K\2]MJ5
MM^1[Y<I6MV.`L439=2BIJ`?Q,HQDF$]#)7'0$5I6*7;JJH24:DJN0IETA.D`
MJ%^U]HO?IGS'97EGXQX;#<Q21316C*X92I1C%#[6!ZJW0]#0]#]FN5_"E]87
MWE;FLUK+%+!+=*R%6#!U[]Q[E(J&7J.HJ.H^T:A;-V<&/S(<^7'&8&2>'M>+
M=W)N_P"QWM%SX^CK4>**JW5!E_[,:=_;8JY^Q/M@X)(>/I[W5YDWN/\`)/CJ
M\IW?GQRT7TO<_&[(E:AZ^[;VJ#KTVF*OZ.J#%):_YY\E;B5!Q]<1-]7VOP.Z
M85W#I[-W?W'I^D)J?IZL3^"*+C&OQE\?G39BS2<O)76)!VY301!==\KIUL9*
MNEE0+[@N%&3-%(QA'R%)(A?S2@'2S_B!FE?RGD4=F**EN`*F@'8C-!]U23_*
M3IJ?PZ0PIXGQSHJAVENB305K]3*M:_;M`'\@`]!JLOAUCN`\BN!&UX)O&C.,
MJ5U/Y*M9AL6NS!0Z3R(V^+BFL[4!9JB4L:+ERP8O$BMW2S8CP%!115(X.B8&
MKS3-<BXSY#L.0\>MA>+:<7MVN8CU#6K.4DK^E0,5-5#;:;F!4,-*/@^$XSR?
MQS?\:Y'=FR:]Y5,EI*/5;L0HT=#\M2H<48KNKM5@Y4B8Z7L_)NEDY[\#>82U
M/U[5LEX)ZU=LYY-UR/;EM5DR1]65VZ5:O3WV"21%Y!R[0=%*OX+F<MU/?%T(
MHNC4M[@^*WQX]Y!X6)[+$7G(+>*:Q=CVTN`]=\0KM]H!6HJNUAMV>Y!<V>>Y
M;CTY+XXYQV+[-67'+J6"_11W'MC'^'*U`WN+*U&HVY3N,E5<J$1XRC./?^GS
MM>@NV8X'5=+4'0UI!5)2NP5HD+HW+2Y.UD.8S=JS`(YZ"*KCLF4J#@.X?;#K
M9;))>1^1K3'*W]XIK4=FGSL@A/=6/XD^Y*@=:E/NUCF=8N.^-KS)LO\`=J&\
M?O[NJ)(;E3&TGP``20U;H%5_@#JR;YRW#:?C>"-*H"I7_(N:YA4":QUG"JD6
ML[>-9-W9;!-LBMC&=H0:4@K&&77``1[IE,8>R8B"O\!(UO+R"^R0V\:CPLRW
M);I&6)&Q37IO*B2@]>I`]=-3^(AUN8N.V&+.[E#YJ)[8)UD"@$,XIUV=PPDG
MTJ`3\M1\O&IG?9+Y.?F4895.URMZ.[J>!MZ5/VR*<6"M0]E/1UR1K^=A6+MD
M\DHULZ$!51353.8OIW#KTY2^.B\5<(DR\<LN,$UV94C8([)W?<$8@A6(]"0=
M>/$$R4OE_GD>&DBBRABLQ$\BED5^UT+*""0#Z@:>#/*9\@U;/=Y/DYN_'"_9
M@3,KPFI!YKD]EI%D)/&B3&C)$T],6:18I1;1$B_OIF2[G\RB`E["/6!R-]XX
MNOIXN*X_)V^5^KB]TTZ2ILW>Y=BH#N/2AKID8ZQ\E6BW,W+<AC+C$BTF]L$+
MQONV':=S&@`ZU_\`1%<>6<)R\[/A0XD4&J6*)I^NT:(87S(+^]6>)(U2WPUY
ML2+]%T_ADG,LR:R,0LLF?V"BHFZ3;J]O)$O9FY?G?^7_`)TS.1O(GFPUPYBN
M(0`>Y&T2%2`U%)#`'J:%2PK[M*C#^/AY&\`X7&V<B0YNV7NVTQ+#MR+-(&!9
M`64,A(Z`D.$:GMU%_P`S>-U3CEPV^/3$ZJL48;/.1=+AP?.E"D>SD@E6IUW9
M;5(BJH915_8;`]</WBIA-W<.C"8>YO6V\'YR\Y/S?DF>O!^_N<;(U!Z(#(@2
M-?L"(`BC]5>FJ7SU@++BG`N,<>LC^XM<G&M3ZNW:<R2-][N6=C^LVF\^3PBW
M$[D#Q4^3NM-7BE>SB9)A/)QO"H`Z7G,/T0ZQ(J85;)>)7RM7FW2PMQ,;[;I=
MH4!`"AUC/%)7F'',OXINV47%RGU=B6-`EU#3<M?AW%`KTZ*'/QUNO+P;A?)L
M-Y=LU9K>VD%I?!`"7M9B0K??L+-MZ]7,0KTTA/."K6R`XU\*N0VP1[QK4=[^
M0&O<H^4*#Q-0T?78.[J,$\>KEG\BJ>Q#T;(HMK$^"X"FBY(<`#S4[&8G`[NS
MN.4YWC6%93>8[CKV%B1\SO%7ZAX_VI;EC)4=2M/@-+/R!97]MQ+`<ISB.MID
M^2KD;\&M$27;]/')ZT2*S7M4;H&J/4];58;!6EHY`XMR^YX[!ETCI#"TN*CP
MYR/-)<[7+*<[NQC?=:D+8'J3.V;5HEABT4W"SM1)"+:D()T6H))E5*HI^0O:
M<<ON&>/;*[7%M$),E<3K6>01?-N0$QVL*&JA02[5H7J:%SV_'$N^36'./)%_
M9ME1-VL9;6[4MXS*:KL<TDNIG`#%B!&M*A**"%L^'(M)B<6^1*RW)HQ+7&?,
MCD(]N;\S)1TL-7@H5NX?^X5BDK(N$V46X=BD1$#*![IP3#R/ZZCS9]?-G>-6
MMB6^I;"68B%:#N.Y`]?:"6"U)Z=!7TUDO!`QT&`Y5=Y!5^D7.WAE-*GMI&I;
MTJQHI>@'7J:=3I8F#2^_&!)8#8\9T:K<M/BVY3['2(^F9E;48Z=MF:SE^ED[
M'59C/W+I`YY!6->(_7(*)D*`O&?BZ:MGHD=CJI'Q_E>+(VV<MI</Y9Q%E*9)
MXR4CG2)=DBR@'H&!V$$GVM5'9*IK)11Y'Q#-C;K`W4.;\09F_B$5O+M>2!Y3
MW$:(L"2RD;P12KK22-)")-=(NUZK!X7DNC['9XR?FJ[F-0G+M.QE69(2-A>1
M-?9*2$@2)9.G;!NY=E:HF,!3K)E[%'N8.N8,%B+CD&9M<):/&ES=3+$C2$J@
M9S0;B`2!7[`==7\AS5MQS"76>O$DDM+.!Y76,!G*H-S;02H)H*]2!]^J\>:M
M?X/<].!]RUJV6B@SM$BLRL5^SC8$).*:V'/+$T@'$E')-GYU0?L))22139R,
M"O\`:=J"+91'WO`2LK@ESS[Q[Y!@PUG%<1W[W20S6Q5BDR%PI)'H5VDLDP^4
M>X-MK56>0;;QWY)\;SYR]FMGL$LWF@N0RB2"0(64`UW!MP"O">K'V%=U*4.\
M5;;I5IT#X)+?R3=RB^?,Y'?ZQG-@MZJ_T3N5@Y^0C\U4=O)$?;._2]F):1:I
MS>XJW:-Q()@+Y==!\NL\7:8WR!9\75!DF6TDF2.E0KH#/0+UI0RLX]`6:M-<
MY<.N\O=93QY><J9SBTDO(X7EZ*2DC+#4MTJ&["QGU(5*5`KJX7:Q1/\`/+PN
M.F*1CEX?[$BN=,2&."B3C1!!)8Q.X^:8*=P*;U#R_EZ2F"W#^'W.!JT_.;<C
M_1!I[9\J?XB\&5I7\FG!_P!%WTTE7!^X52L_#Y\D[.PV*$A7D9IO+^+D&$E(
M-&;QE(S]5C(Z"8+LEE".$W<P_5*@U3\/)=8?`@"8!`-WSNSO+KS5Q>2WBDD1
M[;',"H)!5)69R".E%'5C\!U/32\X'?65KX,Y9%<RQI(MQD%*LP#!GMXU12IZ
MU=CM44ZGH.NM$V_L'P[?$1W$@=N2'&\.XB4.P_47_OV'OZ"'8>_Y/Q]6&`J?
M-/,O_P"9>?ZH=0.1_P#A#A)'_P"M:_ZKG3[6V=@U_P#4"Y2T0FHA=VUX26B&
M=-4)-DJY:S!I^PRA(AT@FN95M*&C#`Y!N<"K"W$%0+X"!NEY:6]PO\.EV[1N
M$.=1@2IH5V1KN!IU7=[:CINZ5KIC7ES;-_$U:1K)&7&!92`P)#;IFVD5J&V^
M[:>NWK2FE1T67A9CY`_F3T>K2T2VS&K\!9+,]`LP/FC6M.=<D*'7V4175Y11
M5..7LWU42Z;%0\Q7%PB9(`$X^([#%PS0^.N$8R[1SE9>1+/"E"7%NLSLSA?4
M)1E:M*4(/IUUBLQ/!/Y(YWE;-T7#P\:D@F>H$9N&@A5$W?*9-R.@%:[E9?7I
MK,V2VT>+_P!-?76]BDHE8]@Q&!IU;8*.&Z[F2OB^J$+%1$:V`QE5YIB]:F6,
MB0!52*W.80`"CVCVMG?R_P`3\K6RN!'?-(YH0%B%O[F8^@4@TJ>A+`?'4^\O
ML='_``L1K<O&3+:+'&*@DR_5U4+^TM"QIU`4D]`=8/\`_-/,O_T=L_Z'O]V/
M]8??XA_P'^;^]?\`9OTW4O\`O5P?]:'_`![W_0?@_P!-_P`O[_351_=#R!^K
M-_XY^G]3^/\`T/\`S/V?770[M%8FWL7!W^E,S/="RJ25M%;8(F*FO9X=5`&M
MUS\5#%,7PN=>*=)N!_Z-*519.#?H`$.:<%=P1RR8V^;;C;Q1&Y/I&P-8IO\`
MI/U/Q,9D7]+75/(K.XD@CRF.7=E;)S)&H]9$(I+!_P!5*A:]!((V/RZJ90V&
MC;>TI6=%LZS7&XS4=COEW?-T'KB;M;R:U^ZO8NEUZ"C47%AE[.6&G$8\L>R1
M7>DD9998B958=02N-L)D,"\^3[0.;>TMH8@2`D86VB#2N[$(L>Y"^]R%*1A2
M:3C2.7/XWD26^)[Q&`2\NIIB`2\I>ZE*Q(B@R-)L<($0,XDD9@`T!HU]G:2L
ML&OS.I8G<:/BFO5JAPM?G(Q&.L]ORQ7.&TL>OV^^9O7"NY"KQ:+QXW>M/H3R
MWW>5GXR:;,IC%+D+5X8?HH,3?P7&=LI9F=&)CCG[Y7?'%,]!(Q`*MO$>_=6(
MN:5V]ZD\XO[C-8ZXMN/7\,*(ZA9);8P!MDLUO'5HU!*NNPR[`M)A&*T6_.>0
MD\PL&,98Q=15BUZIQ.RYMDGT#TLY7K2A/H4)K59E*4:JK$DJEG[5FN[>+`85
M/V;:,W!Q]UV'6GR?&[>2VO\`+R!XL+,]M/<5&QXRAF,BE2!MDF)"J/3OLZ@4
M361Q/*KJ.ZQ^%C*2YZ!+JWMMIWQR!Q"(W#`G=%``S.?7Z=8V/N?5O&<T6-S:
ME0-+BW#E^E#ME!?2[\0-)6&<D'*TG8;++*`(@I+6.<>.'KDP>@K+F[=@[`"6
MRF0ERE_)?2@*7/11\J(`%1%_91`%7[@-/G$8R'#XZ+'PDL(Q[G/S.[$L\C?:
MTCEG;[R=;M_M_((?D'\H#U`U8Z1BZ?&?P/OUHD+K8.,V?MK5+*.%92;J0SV?
MO)-1X;S>'D!H4S6TWHO#^JWN%-[H^INX],"Q\J>0L=:+8V^5N3:(`%639,%I
MZ4[JO2GPIZ?#2XR'B+QMD[MK^ZQ%L+MR2S1;X"Q/J6[+Q@U^-1U^.I9JW$+C
M'1\DL&$T[$J#6,DMA`):J5!Q`1L?9NRB2ON6%VU53E9IP8R)0,JY<*J&*'B(
MB41`::[YIRN_S,?(+V_N)<Q"?W<K-N,?_P!`?:HZ^B@#X^NKNSX+Q#'X.7C=
MEC[:+"3BDD2KM$E*?.0=SGH.K,33IZ:R.:\6N/>.46V9EEN45:B4"\IO$K74
MZXB\CX>7)(,%(M[[C=-X(MC.F*IDSF0%(QN_<1\O7KSRG+N29O(0Y7+7DUQD
M;<CMR/0LM#N'6G6AZ]:Z]<3PSB^"QT^(P]E#;XVY![L:5"ON7::BO2J]#2G^
MG40I?&]P60J\K24.,F9MJE.3D+9I>OM6$@VC)"PUU*21A9IRV0D2%4DH].7<
M`17\\?<[F$1*7QN3Y/Y^UVE^V5NC>1QLBN2I8(Y4LH)7T)5>GW=/CJC7Q/XY
M2T>P3$6JV<DBNR`,%9T#*K$!O4!V'\AZ_#4D9)P]XRX7&7B)RW':M7&VF,SQ
MF@N'/WG99BY11V:T>,/8K!:Y";G92&*Q<'2(T5<F;$(80*0._59F>;<JY!-;
MSY:]FE>U;="!M18VJ#N1(PB*U0#N"[B?4ZM<'P/B''(+BWPUA#%'=KMF)W2-
M*I!7:[R,[LM"1M+;:'TUJ%%^/WA=FU$O694[CEF["AZ8FS1O59D(US9&%B;Q
MJ[IU%M70V5Y+N$&<2\>K+M$4#I)M5U#*)%(<1-U-R'D?G.4R%OE+W)W39"UK
MVG#!"A8`,1L"@E@`&)!+``&HZ:A8[QCP'$X^YQ=CBK5;"\IWD8&0/M)9:F0L
M0%8EE`("L2RT/763QK@UQ+X_VP+[DN(52L79.,-"LK:Z7G+58X>&,`D-$5^8
MN$M/OJY%F2,)!;L3MTA3$2B7Q$0Z\LYY`YER.S_+LQ?S2V!;<8P$C1F_6=8U
M0.WQJX8UZUKKTP'CCA'%[W\RP>.AAR`3:)"7D=5_51I6<QK3I1"HITI369SO
MASQAR;1Y#7LWQ:FT_3I8989:[Q#=ZE/ROWX8YI7[S>*O51D/JS*"(^\!_#^;
MX^G4?)\WY7F,8N%RE]/-BDV[8F(V+L^7:*=*?=_/J3BN!</PF5;.8FP@@RS[
MMTJ[M[;_`)MQ+&M?OK]VI@T;.*-KE+GLZTJLQEQH]G;HM+!6IA-16,E6R#I!
MZD@[3241.=(KIL0_;R`!$OKW#TZI<9E,AA;Z/)XN5X+^(DHZ_,I(()%:_`D:
MO<MB<;G,?)BLO"D^.F`#QM\K`$$`TI\0#K4<5X]XGQSK\E5,-S6L9A6Y>4&:
MDH6JM%&4<ZE1;)-!>F;'65(18S=`I1\/$![=Q#OZ]3<[R7.\GN4O,_=2W=TB
M;5:0U(6I-*T'2I.H/'^+\?XK;/9\=M(K2UD?>RQ@@%J4K2IZT&M.VOASQ=Y'
M3T79]UQ"AZE/PD5]R1,G;HQ217CXKZE9Y]&U`7!$DDQ<N#G$0+Y")O4>W;J=
M@>;\MXQ;O:<?O[BTMY'W,L;4!:@%3T^P#4#D'`^'<KN4O.1X^WO+F--BM("2
M%J30=1TJ2=*!S'S6>M[3C/\`'MC6.S[#`]#LD`^W6Y1E;>+9KG/'[*Y1O;%\
M]+8G9%V3.T:+,0:$<U2]TSA)L)Q[![R9@VG",I;V3Y3R3F[V-N16T3BUB9P)
MYKNX4QB;8*$QPJY=C2A:GZI&L)SW$7%_'B?%^!L94XU=2H;N58R8(;.W82&#
MN'HLDS($7J6`^'O!%E%QH5(T*H3&?7FI5VW46?C1AYFHV*(8RM>DHOQ(4C)U
M%/$56BB*/ME%/[/=(Y"F((&*`@K;+(W^-O4R6/FEAR$;;ED1BKJWVA@:U^W[
M>H/KIMW^,QV4L'Q>1@BGQLJ;6B=0R,OV%2*4'2GV$`BA&EHS+X_^&V./GTGG
M.!4^`DGT#,5<K]9Q8)YY$5VP-56,W#59S8YF76IS"49+G16)$BR`Z1A+^#TZ
MU65\C\WS<:Q9/(S21+(LE`$0,Z$%6D"*HD*D`@R;J'KK(XCQAP+!2O-B\;!'
M,\;Q[B7<JD@(=8S([&(,"0>WMJ.FMRR7A_QDPA.WH8_B]+SU"_19X6YH5QHZ
M:(66-5*L15O*HF=JI.3JD<'`RH@"I@,(";MU!S/->5\@,+9J^GN6MWW1%R"4
M;IU7IT]!T]/NU/PG!.(<<$ZX.P@MEN8]DH0$"1>O1A4U]3U]?OU'F=_'3PDR
MBWU>]Y_QUH]?LU(6^KIKD%)^3C:K(^T5$9FO5V9F9"NQ$^<I0$T@@T(].I]L
M51/]KJRR7DSG>8LI<=D<E/):3BD@HBM(OZKNJJ[)^P6*TZ4ITU68OQ7X^PU_
M%D\;BX([V`UC-9&5&_71'=D5^E=X4/7KNKUTW=CKT+;J]/52RQR$Q7;1#2E>
MGXEUY_32D+-,EXZ4CW'MG(I[+QDY.F;Q,4WB8>P@/6,M;F>RN8[RU8I<Q2*Z
M,/564AE(^\$`ZW%W:6]_:2V-V@DM)HV1U/HR."K*?N()&D(#XF?CD*YBW)>)
MF:%")3CDVS$IK(2&<FBDDT63F8@"3Q82??%33#W'#YNX77-W,J<YA$18G^<7
MDW8Z?G%U[R:GV;AN-2%?9N0?8$*@?`"FEK_DIXL[B2?DMKN0``5DVF@I5DW[
M7)_2+ABU3N)J=-)JG&_!MNSAED6J9/2[CFL5]W#"5!]$(M(NNGAT?IHE:L?=
M?T+FLN(UK_1(*,%&ZB20B0H@41#K)8CE'(<#DVS6(O)X<H]=T@8EGW&K;]U0
MX8]2'#`GJ>NMCF>)\:Y!B5P>8LK>?$I39$5HJ;11>WMVF.@Z`H5('3TU2Z]Q
M6#POY<.+,CB?'+8(#C[EF-7[-[5<*WEVCV"E-=%T]:RNVDBZN;YO+.;`T6";
M9ED)<[EP@U$!*JJ4$3^#S3.W'(/#F63.Y.RDY'=WL4\<;W$"2F&#M@J(@5"$
M;&V1A06]0/<*H)\#:\:\U8EN/XJ_BXU9V<D,DL=M</$)IQ/[C*0Q<?O(P\I9
M@OH3132T2;^/+A#8]"L.J3W&/)I>]VQQ(/++-/JZ5PA-2$HBX0D)5_"'6&`6
MF7172AC//I?JO<4,H"@'$3=*:W\E<]M<;'B;?*WB8^$`(H>A4+0A0_SA10>W
M=MH`*4Z:<%SXM\>7F3DS%UB+*3(3%B[,E0S-7<Q2NS<:DEMNZI)K7KKY7OQT
M<'I*KUZDR'&G-7E1J;V3D:S6W+!^M#0+^9%N:2>13`\B+=DX=&:)B)TRE$H@
M/CV\C=_N/R;SZ*[DOH\I=+>3*JNX*AG"UVACMJ0*GU_]M?$GBKQW-:1V$N)M
M6LH69D0ABJ%Z;BHW4!-!7_YU[T;XZ^$FL2\58KWQSH4I9H:-BHAA:H\)JL6P
ML?!QZ$3$HN[15I:%GY([",;)MTU'+E54$B`7R$`[=?F,\F<\P\+VV/R=PEJ[
MLQC.V2.KDLQ$<BLBU8DD*H%36FOW*^*_'N:F2YR.*MGND15$B[XY-J*%0&2-
MD=MJ@`%F)H/74D5;B/QCI>22^#5O"LT88_8E%'%CH"M8824%9'BBR3@TE8R2
MB;US/RX+MTU"O'BBSDITB&*H`D*(5=WS/E=]F4Y#<Y"Z;-1"B3!RKH.HVIMH
M$6A(VJ`I!/3J=6UGP?B%A@Y.-6N.M%P4O5X3&&20]/<^ZI=A049B6%!0]!J(
M:+\9_`_-K5#7.F<9Z!%SU<E1G:\+H]@G8:`F_(#EF82KS\U*5B)EDSE`Q'+=
MFFL0P`)3`(!U=9#RIY!REF]C?92X>WD3:]-B,Z_JM(BK(R_:I8@_$:H\=XC\
M<8F]3(V.)MUNHVW)4R.J-THRQN[1JPH*$*"*"GIIZ.X_E_'W_P"/Y>E_IC:`
M_"'^\/\`MZ-&N:6V_P"=NX?JS]U[3_D\_>?_`!7U']4?V_\`B[_Y_P"NZZFL
M_P#`4/S_`(T?_<OP_P"KP?-]W]G_`.%V]<@7_P#Y$G^3\&7_`+7^)_6;CY?O
M_M7_`!NYJ:D?TJ?_`%'/S@_0_I?_`"_^;JC/RG_#'I\=:1?F'^+/YO77X?&M
M_F3U#_"O]\+E^]G^,_[E5C]U?_L?\9?V;Z#K]\I?X6M/ZY^!'^'_`%;\63\3
M]C^S?M=S7GXB_P`7WG]2_'E_$_K?X4?X?_$_M7[/;U?MUSIKI_1T:-'1HT=&
MC1T:-'1HT=&C1T:-'1HT=&C1T:-'1HT=&C7K^:/YWX?_``_B_#_+T:->>C1H
MZ-&CHT:.C1HZ-&CHT:.C1KW^+^?^#_A_W=&C7CHT:.C1HZ-&CHT:.C1HZ-&O
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
